Call for probe into US job “outsourcing” via recruitment of overseas staff

By Gareth Macdonald

- Last updated on GMT

Related tags Outsourcing

US Congressman Joe Courtney (Democrat, Connecticut) has called for an investigation of current visa laws that he says may have allowed global drugs giant Pfizer to “outsource” R&D positions at its facilities in the state.

Courtney has asked the Government Accountability Office to assess whether the H-1B visa program, which is designed to help firms recruit small numbers of specialised workers, is being used to circumvent strict US labour laws and bring in many overseas staff.

The move follows reports that Pfizer is using large numbers of foreign workers at their preclinical R&D campuses in Groton and New London, Connecticut, in a effort to replace their local IT workforce, according to local newspaper The Day​.

The paper said that the workers are sourced by Indian agencies Infosys Technologies​and​Satyam Computer Services rather than Pfizer, which said claims to employ only 60 members of staff through the H-1B scheme.

In an interview, Courtney said that former Connecticut congressman Bruce Morrison, an opponent of H-1Bs, told him that rules governing the use of the guest worker programme are unclear and that that Pfizer's actions may be entirely within the law.

He also said that the outgoing Bush administration “has been pathetic in terms of upholding the law​” in terms of employee protection.

It is unclear how US President-elect Obama’s incumbent government will view firm’s that seek to bring in overseas workers, given his somewhat contradictory campaign pledge to both reduce drug costs, lower the number of jobs outsourced overseas but not shy away from globalisation

Related news

Show more

Related products

show more

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Follow us


View more